[The changes of natural clotting and fibrinolytic inhibitors in collagen and collagen like diseases (author's transl)].
D000933:Antifibrinolytic Agents / Q000032:analysis*; D000990:Antithrombin III / Q000032:analysis; D003174:Complement C1 Inactivator Proteins / Q000032:analysis; D005341:Fibrinolysin / Q000037:antagonists & inhibitors; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000097:blood*; D013919:Thromboangiitis Obliterans / Q000097:blood*; D000515:alpha 1-Antitrypsin / Q000032:analysis; D000511:alpha-Macroglobulins / Q000032:analysis
D000933:Antifibrinolytic Agents; D003174:Complement C1 Inactivator Proteins; D000515:alpha 1-Antitrypsin; D000511:alpha-Macroglobulins; D000990:Antithrombin III; D005341:Fibrinolysin